SAB Biotherapeutics (NASDAQ:SABS) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS

SAB Biotherapeutics (NASDAQ:SABS) announced its quarterly earnings results on Wednesday. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05), Zacks reports. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.04%.

SAB Biotherapeutics Trading Down 17.2 %

Shares of NASDAQ:SABS opened at $3.27 on Friday. SAB Biotherapeutics has a fifty-two week low of $2.16 and a fifty-two week high of $9.72. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.07. The firm’s 50-day simple moving average is $2.89 and its 200-day simple moving average is $3.02.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SABS. HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of SAB Biotherapeutics in a report on Monday, August 12th. Oppenheimer reiterated an “outperform” rating and set a $12.00 price target on shares of SAB Biotherapeutics in a research note on Thursday, September 12th. Chardan Capital restated a “buy” rating and issued a $25.00 price objective on shares of SAB Biotherapeutics in a research note on Thursday. Finally, Craig Hallum initiated coverage on shares of SAB Biotherapeutics in a research note on Wednesday, October 9th. They set a “buy” rating and a $11.00 target price for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, SAB Biotherapeutics has an average rating of “Buy” and an average price target of $12.40.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.